Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Traveler's Diarrhea Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Traveler's Diarrhea Overview | 8 | 1 |
| Pipeline Products for Traveler's Diarrhea Comparative Analysis | 9 | 1 |
| Traveler's Diarrhea Therapeutics under Development by Companies | 10 | 1 |
| Traveler's Diarrhea Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Traveler's Diarrhea Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Traveler's Diarrhea Products under Development by Companies | 15 | 1 |
| Traveler's Diarrhea Products under Investigation by Universities/Institutes | 16 | 1 |
| Traveler's Diarrhea Companies Involved in Therapeutics Development | 17 | 6 |
| Cosmo Pharmaceuticals NV | 17 | 1 |
| GlaxoSmithKline Plc | 18 | 1 |
| Nippon Shinyaku Co., Ltd. | 19 | 1 |
| Prokarium Limited | 20 | 1 |
| Scandinavian Biopharma Holding AB | 21 | 1 |
| Sigmoid Pharma Limited | 22 | 1 |
| Traveler's Diarrhea Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 12 |
| Etvax Drug Profile | 32 | 2 |
| GVXNSD-133 Drug Profile | 34 | 1 |
| IMSUTMR-1501 Drug Profile | 35 | 1 |
| prulifloxacin Drug Profile | 36 | 2 |
| rifamycin CR Drug Profile | 38 | 2 |
| Typhetec Drug Profile | 40 | 1 |
| Vaccine for Traveler's Diarrhea Drug Profile | 41 | 1 |
| Vaccine for Traveler's Diarrhea Drug Profile | 42 | 1 |
| Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea Drug Profile | 43 | 1 |
| Traveler's Diarrhea Dormant Projects | 44 | 1 |
| Traveler's Diarrhea Discontinued Products | 45 | 1 |
| Traveler's Diarrhea Product Development Milestones | 46 | 7 |
| Featured News &Press Releases | 46 | 1 |
| Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX | 46 | 1 |
| Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers Diarrhea | 46 | 1 |
| Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea | 47 | 1 |
| Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) | 48 | 1 |
| Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting | 49 | 1 |
| Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria | 49 | 1 |
| Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers | 50 | 1 |
| Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting | 51 | 1 |
| Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial | 51 | 1 |
| Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study | 52 | 1 |
| Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers Diarrhea | 52 | 1 |
| Appendix | 53 | 2 |
| Methodology | 53 | 1 |
| Coverage | 53 | 1 |
| Secondary Research | 53 | 1 |
| Primary Research | 53 | 1 |
| Expert Panel Validation | 53 | 1 |
| Contact Us | 53 | 1 |
| Disclaimer | 54 | 1 |